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number of future HCV related complications, reduce costs and increase the 
number of QALYs experienced.  
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OBJECTIVES: The purpose of this study is to compare the direct cost parameters 
on rheumatoid arthritis (RA) by using two studies in Turkey conducted via 
patient database record system and via expert opinion methodology in 2010. 
METHODS: The data included in this study was collected upon the opinions of 
22 rheumatologists from 53 clinics in Turkey. The other study was completed by 
Turkish Health Insurance Funds Database (THIFD) —1920 patients selected for a 
6-month period. RESULTS: Based on the patient database, 5% of the patients 
were hospitalized and 42% had outpatient visit. According to expert opinion, 
7.2% of the patients were hospitalized and 77.12% had outpatient visit. Patient 
records state that non-COX inhibitors (78%) and immunosuppressants (71%), and 
disease-modifying anti-rheumatic drugs (DMARDs) (11%) of the patients were 
prescribed and biologic DMARDs are not specifically stated. Based on the 
rheumatologists, non-COX inhibitors (34.52%), immunosuppressants (39.76%), 
methotrexate (80.86%), sulfasalazine (31.76%) and biologic DMARDs (17.15%) were 
prescribed. Total annual cost (EUR€2,386) results of the patient database system 
comprised of pharmacy costs (EUR€1,747), outpatient costs (EUR€360), and 
inpatient costs (EUR€252). Annual cost from expert opinion was EUR€2917.03 
with outpatient & inpatient costs (EUR€206.82) and pharmacy and 
prostheses/orthoses cost (EUR€2710.21). CONCLUSIONS: Expert panel 
methodology’s important way to observe the real world practice. It’s observed 
that expert panel and patient database results are in line with each other. Due to 
the distribution of the pharmaceuticals, a difference of only EUR€531.03 was 
found. It can be observed that biologic DMARDs treatments are perceived to be 
prescribed more, however according to patient data, prescribed ratio of biologic 
DMARDs is relatively low. THIFD is used to extract patient costs where patient 
records are used for controlling reimbursement criteria, so some of the data may 
be misleading. Accurate performing of coding is key issue to minimize possible 
bias in use of patient data.  
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OBJECTIVES: The purpose of this study is to compare the direct cost parameters 
on ankylosing spondylitis (AS) by using two studies in Turkey conducted via 
patient database record system and via expert opinion methodology in 2010. 
METHODS: The data included in this study was collected upon the opinions of 22 
rheumatologists from 53 clinics in Turkey. The other study was completed by 
Turkish Health Insurance Funds Database (THIFD) —1920 patients selected for a 
6-month period. RESULTS: Based on the patient database, 7% of patients were 
hospitalized and 46% had at least one outpatient visit. According to expert 
opinion, 8.2% of the patients were hospitalized and 66% had outpatient visit. 
Patient records state that non-COX inhibitors (71%), and disease-modifying anti-
rheumatic drugs (DMARDs) (35%), are prescribed. Based on the rheumatologists, 
non-COX inhibitors (81.37%) and immunosuppressant (7.52%), methotrexate 
(13.21%), sulfasalazine (40.24%), non-steroidal anti-inflammatory drug (81.37%) 
and biologic DMARDs (24.95%) were prescribed. Total annual cost (EUR€4,233) 
results of the patient database comprised of pharmacy costs (EUR€3,760), 
outpatient costs (EUR€297), and inpatient costs (EUR€155). Annual cost from 
expert opinion was EUR€3,565.91, with outpatient and inpatient costs 
(EUR€239.57), and pharmacy and prostheses/orthoses cost (EUR€3,326.33). 
CONCLUSIONS: Expert panel methodology’s important way to observe the real 
world practice. It’s observed that expert panel and patient database results are in 
line with each other. Due to the distribution of the pharmaceuticals, a difference 
of only EUR€239.58 was found. It can be observed that biologic DMARDs 
treatments are perceived to be prescribed more, however according to patient 
data, the prescribed ratio of biologic DMARDs is relatively low. THIFD is used to 
extract patient costs where patient records are used for controlling 
reimbursement criteria so some of the data may be misleading. Accurate 
performing of coding is key issue to minimize possible bias in use of patient 
data.  
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OBJECTIVES: To describe the real-world clinical complications associated with 
recurrent venous thromboembolism (VTE) and to quantify the incremental direct 
all-cause and disease-related health care costs associated with recurrent VTE. 
METHODS: An analysis of health care insurance claims from the Ingenix 
IMPACTdatabase was conducted. Between January 2004 and September 2008, 
subjects aged ≥18 years on the date of first recurrent VTE diagnosis requiring 
hospitalization (index recurrent deep vein thrombosis [DVT], pulmonary 
embolism [PE], or both) with ≥12 months of baseline observation prior to the 
index recurrent VTE were matched 1:1 with control VTE patients without 
recurrence, based on exact matching factors and propensity scores. The 
proportion of patients with post-thrombotic syndrome (PTS) was calculated for 
up to 1 year and compared between the two groups. All-cause health care and 
disease-related costs (thrombocytopenia, superficial venous thrombosis, venous 
ulcer, pulmonary hypertension, stasis dermatitis, and venous insufficiency) per 
patient per year (PPPY) were also calculated and compared between the two 
groups. RESULTS: The recurrent VTE and VTE control cohorts (8,001 subjects 
each) were well matched for age, gender, comorbidities, VTE risk factors 
distributions, and baseline health care costs. The risk of PTS was 18.1% for the 
recurrent VTE cohort and 6.8% for the no recurrent VTE cohort (risk ratio: 2.7  
[2.4 - 2.9]). Patients with recurrent VTE had significantly higher average PPPY all-
cause costs compared to control patients (mean: $86,744 versus $37,525, cost 
difference=$49,219; 95% CI=46,253–51,989). Corresponding disease-related health 
care costs PPPY were also significantly higher for the recurrent VTE group (mean 
$11,120 versus $1,262, cost difference=$9,858, 95% CI=$9,081-$10,476) and 
represented 20.0% ($9,858 of $49,219) of the all-cause cost difference between the 
two groups. CONCLUSIONS: In this large matched-cohort study, recurrent VTE 
patients had a significantly higher risk of PTS compared to VTE control patients 
and were also associated with a significant health care cost burden.  
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OBJECTIVES: The phosphate binders sevelamer hydrochloride (SH) and 
lanthanum carbonate (LC) will be included in the Medicare bundled 
reimbursement scheme from 2016. The aim of this study was to evaluate the 
cost implications of switching patients from SH to LC monotherapy. METHODS: 
A post hoc analysis of the cost implications of switching from SH to LC 
monotherapy was performed using data from a 16 week, phase 4, real-world 
clinical study (n = 953). Daily LC doses were titrated to maintain the level of 
phosphate control achieved with SH at baseline. Costs of mean daily drug doses 
were calculated using the average wholesale price (LC 1000 mg: $8.82; SH 800 mg: 
$3.71). Analyses were performed by baseline SH dose group (per mean daily dose) 
and by real clinical doses of SH and LC. RESULTS: Mean (SD) serum phosphate 
levels were 5.88 (1.69) mg/dL at baseline and 5.93 (1.85) mg/dL after 16 weeks of 
LC treatment. Mean doses and associated costs by baseline SH dose group were 
as follows: SH 2400–4800 mg/day: 4051 mg/day ($18.79/day) versus LC 2445.4 
mg/day ($21.57/day); SH >4800–7200 mg/day: 7047 mg/day ($32.68/day) versus LC 
2823 mg/day ($24.90/day); SH >7200–9600 mg/day: 9253 mg/day ($42.91/day) 
versus LC 3018 mg/day ($26.62/day); SH >9600 mg/day: 13 150 mg/day 
($60.98/day) versus LC 3156 mg/day ($27.84/day). Analysis by real clinical doses 
revealed that LC 3000 mg/day ($26.46/day) is less costly than SH 6400 mg/day 
($29.68/day) and 7200 mg/day ($33.39/day), but not SH 5600 mg/day ($25.97/day). 
At baseline, 65% of patients were receiving SH ≥6400 mg/day. CONCLUSIONS: 
Our analysis showed that LC is more cost-effective than SH in patients taking SH 
≥6400 mg/day (65% of patients at baseline). Switching these patients to LC 3000 
mg/day would offer cost savings, a reduced daily pill burden (3 vs >8/day) and 
effective maintenance of phosphate control.  
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OBJECTIVES: To evaluate the cost-effectiveness of prescribing branded 
Taxotere®compared to its generic counterpart docetaxel for patients diagnosed 
with breast cancer in the UK NHS. METHODS: A previously published decision 
tree model was populated and developed with the Vial et. al. and Brown et. al. 
trial data to assess the cost-effectiveness of using branded Taxotere®versus its 
generic counterpart docetaxel from the UK NHS perspective. RESULTS: If the 
branded Taxotere® was promoted as the first-line therapy, it would cost the UK 
NHS £411.54 per vial per patient with 0.434 QALY gain compared to £412.98 with 
0.418 QALY gain if the generic docetaxel was promoted instead and failed the 
therapy. Although the acquisition cost of docetaxel is more than 50% less than 
that of Taxotere®, promoting the generic docetaxel based on its lower acquisition 
cost, only, would result in increasing the total health care cost compared to 
Taxotere®. CONCLUSIONS: Based on the decision tree model generated in this 
study, promoting the branded Taxotere® is more cost-effective compared to its 
generic counterpart docetaxel. This should be considered for implementation in 
practice and for future guidelines.  
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OBJECTIVES: Previous studies have documented the impact of otitis media 
among children, but recent estimates of cost of otitis media (OM) among children 
in the United States (US) are not available. The objective of this study was to 
estimate the incremental direct medical expenditures of treating OM among 
children in the US. METHODS: Retrospective analysis was conducted using the 
2010 Medical Expenditure Panel Survey (MEPS) data. Among all children (age<18 
years; n=8,710), those with OM were identified using International Classification 
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of Diseases (ICD)-9 diagnosis codes 381 or 382. Incremental total expenditures 
associated with OM were estimated using a regression model adjusting for age, 
gender, race, ethnicity, education, geographic region, insurance status and 
number of medications used (proxy for comorbidity). Given the skewed 
distribution of expenditure variables, multiple model specifications including 
ordinary least squares regression, generalized linear model (GLM) with Poisson, 
gamma and negative binomial variance functions were evaluated. RESULTS: The 
prevalence of OM among children in the US was estimated at 11.32%, i.e., 8.47 
million persons (95% CI: 10.30% to 12.33%). A majority of children with OM were 
male (51.7%), white (84.2%), and insured (97.3%) with mean age of 4.7±0.20 years 
and education of 0.9±0.11 years. In unadjusted analysis among patients with OM, 
physician office visits comprised the largest proportion of total expenditures at 
$769.06 (SE: 54.99), followed by prescription medications at $606.56 (SE: $41.72), 
and inpatient visits at $500.73 (SE: $148.42). After controlling for covariates, 
children with OM had 48% higher total expenditures than those without OM 
(Estimate: 1.48; p=0.001). The annual adjusted mean incremental total 
expenditure associated with OM was $543.10 (SE: $192.0; p=0.005) per person. 
CONCLUSIONS: Given the prevalence of OM in children and its associated 
incremental expenditures, the annual direct medical expenditure for treating OM 
in children is estimated at approximately $4.6 billion in 2012 US dollars.  
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OBJECTIVES: To estimate direct medical costs in non-cystic fibrosis 
bronchiectasis (NCB) patients with exacerbations. METHODS: An observational, 
retrospective cohort study was conducted using data from MarketScan claims 
database. Bronchiectasis patients were identified as those with a medical claim 
with ICD-9 codes of 494.0 or 494.1 anytime between July 1, 2009 to June 30, 2010. 
The first bronchiectasis-related claim during this period was defined as the 
index event. All patients had to have no other bronchiectasis related medical 
claim 12-months before the index event and no cystic fibrosis related medical 
claim (ICD-9 code:277.0) 12-months before and after index event. NCB patients 
were divided into two cohorts. Each NCB patient with exacerbation (NCB-E) was 
matched to three NCB patients without exacerbations (NCB-W) on geographic 
region, health plan and gender. Medical resource use and expenditures were 
estimated for 12-months before and after index event and compared between 
the two cohorts using non-parametric univariate statistical tests. RESULTS: 897 
NCB-E patients were matched to 2,691 NCB-W patients. NCB-E patients were 
older (67 vs. 64, p<0.01), had greater overall comorbidity as estimated by the 
Charlson’s comorbidity score (1.83 vs. 1.66, p=0.01), and respiratory/chest-related 
symptoms (73% vs. 66%, p<0.001) at baseline compared to NCB-W patients. Total 
average costs per patient post index-event were significantly greater among 
NCB-E versus NCB-W patients ($35,718 vs. $26,868). After adjusting for baseline 
health care expenditures, the overall annual average incremental burden due to 
exacerbations were estimated to be $7,643. Of this, inpatient hospital costs 
accounted for $5,772 or 75% of this burden. Bronchiectasis-related total costs 
were also significantly (p<0.001) higher in the follow-up period among NCB-E 
patients compared to NCB-W patients ($4,609 vs. $1,210), even after adjusting for 
baseline consumption. CONCLUSIONS: NCB patients with exacerbations have 
greater medical expenditures than those without. Effective management of 
exacerbations may be the key in controlling economic burden in this patient 
population.  
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OBJECTIVES: To estimate the direct medical costs associated with managing 
complications of type 2 diabetes in the United States. METHODS: A combination 
of direct data analysis and microcosting was used to estimate costs for an event 
leading to either a hospital admission or outpatient care, and the post-acute care 
associated with managing macrovascular, microvascular, and other 
complications. Data were obtained from many sources, including inpatient and 
emergency department care databases, national physician and laboratory fee 
schedules, government reports, and published literature. For each complication, 
the event year costs derived refer to those associated with the acute episode and, 
when appropriate, include subsequent ongoing care provided within the first 
year following the acute episode. Annual costs after the first year for the 
continued management of complications were also estimated. All costs are 
reported in 2012 USD. RESULTS: Annual costs accrued per patient in the year of 
the event were estimated for the following macrovascular complications: 
myocardial infarction $56,445, ischemic stroke $42,119, congestive heart failure 
$23,758, ischemic heart disease $21,406, and transient ischemic attack $7,388. 
Event year costs per patient for microvascular complications were: chronic 
kidney disease $71,714, lower extremity amputations $9,041, blindness  
$2,862, and diabetic foot ulcers $2,147. Cost estimates of a medically managed 
hypoglycemic episode were: $176, $1,311, and $16,478 for a mild, moderate, or 
severe (i.e., requiring hospitalization) episode. CONCLUSIONS: This study 
provides updated and additional estimates of the cost of diabetic complications 
in 2012 USD, following the methodology used to generate prior cost estimates in 
2000 USD referenced in many diabetes economic models (O’Brien et al.  
Clin Ther 2003;25(3):1017-1038). Managing complications results in substantial 
costs to the health care system, as macrovascular complications yield high 
inpatient care costs in the event year, and long-term management of 
complications such as chronic kidney disease lead to substantial ongoing annual 
costs.  
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OBJECTIVES: São Paulo is a Brazilian state with the largest number of cancer 
reference hospitals and hosts 21% of country population. This study aims to 
describe hospitalization patterns and costs for renal cell carcinoma (RCC) in 
public hospitals in São Paulo state, Brazil. METHODS: A retrospective analysis of 
São Paulo public hospital admissions for RCC was developed according to ICD-10 
classification (C64) as reported in Brazilian Hospital Information System 
(SIH/DATASUS) database from January 2007 to December 2011. Admissions were 
categorized into surgical (containing any surgical procedures codes at 
hospitalization data eg.: tumor excision, biopsy, etc.) or clinical (all non-surgical 
eg.: chemotherapy, infection treatment, anemia, etc.). Costs represent federal 
reimbursement values for hospitalizations (includes medical procedures, exams, 
medications and taxes), presented in 2012 Brazilian Real (BRL). Average 2012 
exchange rate was 1,9544BRL/USD. RESULTS: In the period, 4,138 hospital 
admissions were identified (951, 1,126, 1,207, and 854 for 2007, 2008, 2009, and 
2011, respectively), and total cost was 5,472,534BRL, which represents 0.78% of all 
cancer in-hospital treatment in the state. Mean cost per patient was 1,326BRL, 
675BRL, and 1,854BRL for all hospitalizations, clinical and surgical procedures, 
respectively. Surgical procedures were responsible for 55.07% of cases, and 
77.29% of total costs, with partial or total nephrectomy representing the main 
cause (48.9%). Mean length of stay was 6.99 days. In-hospital mortality rate was 
9.98% for all cause (17.7% and 3.69% for clinical and surgical procedures, 
respectively). When compared to the national cases, São Paulo represents 29.74% 
of them, while representing 33.18% of total national hospitalization costs related 
to RCC. CONCLUSIONS: RCC hospitalizations costs in São Paulo are responsible 
for less than 1% of all cancer in-hospital treatments in the state, which may 
suggest under-diagnosing when compared to international incidence rates. São 
Paulo is an important RCC treatment center in Brazil, capturing about one third 
of country resources.  
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OBJECTIVES: To determine the cost and health care resource utilization 
associated with asthma management in Canada. METHODS: A systematic 
literature search of PUBMED, EMBASE and EMCare electronic databases using 
relevant search strategy was conducted from 2000 until 2011 to identify articles, 
published in English, that reported the data on the clinical and economic burden 
of asthma in Canada. Two investigators independently screened citations, 
reviewed studies, assessed study quality and abstracted data. Heterogeneity in 
study design, data sources and asthma definition precluded meta-analysis of 
study outcomes. All costs were reported in Canadian dollars and inflated to 2011. 
RESULTS: Of the 570 citations identified, 67 full-text articles were reviewed, of 
which 33 studies met inclusion criteria. Both children and adults with asthma 
averaged less than one emergency department (ED) visit per patient per year. In 
children, frequency of visits was largely influenced by the presence of prior 
asthma exacerbations. In adults, increased ED visits were associated with 
inappropriate use of asthma medication. ED visit rates were significantly higher 
in women than in men and, increased with age. Hospitalization rates in children 
decreased with age and patients with persistent asthma were more than one and 
a half times admitted more often than those with non-symptomatic asthma. 
Average hospitalization costs per acute asthma episode ranged from $458 to $923 
and the average costs for ED visit per acute asthma episode ranged from $219.08 
to $276.76, excluding medication cost. The average annual cost of asthma 
medication was $230.58 per patient. Annual productivity loss days in adult 
asthma patients varied from 12 in employed persons to 20 in students and 49 in 
disability pensioners. CONCLUSIONS: The available evidence shows that the 
asthma-related costs, both direct and indirect remain substantial. The overall 
burden varies based on whether studies reported costs from the perspective of 
an individual asthmatic or from the population level.  
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OBJECTIVES: To describe treatment patterns, direct costs and comorbidities in a 
population of patients with melanoma. METHODS: Starting from ARNO 
Observatory, an Italian population-based patient-centric system through record 
linkage of 11 million inhabitants, we identified a cohort of patients with 
melanoma (ICD-9 code: 172 and/or V10.82) during 2009. Discharge records, 
reimbursed prescription patterns, lab tests and diagnostic examinations were 
